Cipla Reports Rs 1,351.17 Cr PAT in Q2 FY26 Performance

Reflecting strong operational performance and consistent market momentum, Cipla Limited has reported a rise in both revenue and profitability for the quarter and half year ended September 30, 2025. The company's performance points out steady growth in its main pharmaceutical units, which will be supported by the strong domestic and international market demand.

Cipla reported the net profit of the quarter ended on September 30, 2025, compared to the previous quarter of 1,297.62 crore and the same period of the previous year of 1,302.53 crore. The quarter total income has increased to Rs 7,858.39 crore increasing by a margin of Rs 7216.03 crore in both quarters compared to the same month of 2024 with an increase of almost 248.73 crore.

Also Read: Bridging Collaboration Gaps to Boost India's Pharma Discovery

In the half year ended September 30, 2025, Cipla has reported a total income of Rs 15,074.42 crore, which is an improvement of Rs 14,095.76 crore during the same period in the previous year. During the half-year 2011-2012, the net profit of the company was Rs 2,648.79 crore as compared to the previous half-yearly results of 2010, which were at Rs 2,480.17 crore.

The steady growth in revenue and profit accentuates the value of Cipla with regard to operational effectiveness, good product variety, and robust international presence. As the company expands its presence on major markets, with the strong focus on healthcare innovation, Cipla ensures its role as a leader in the pharmaceutical sector of India, which promotes the consistent growth in the spheres of therapeutic and specialty.